Samsung Biologics Makes Its Bid for the Global CDMO Crown

Samsung Biologics Is Rewriting the CDMO Rulebook

Samsung Biologics is launching a tender offer for Polypeptide Group, the Swiss-based peptide contract manufacturer, at CHF 44.31 per share – a 11.6 percent premium over the stock’s 60-day volume-weighted average price. If every share tendered, the deal comes to CHF 1.46 billion, or roughly 2.7 trillion Korean won. It would be the largest M&A transaction in South Korea’s pharmaceutical and biotech sector, and arguably the most consequential CDMO consolidation move in years.

The acquiring vehicle is Samsung Peptide, a special-purpose company set up in Switzerland. Samsung Biologics published the formal tender offer prospectus on its website on August 31, and the offer window opens September 15 and runs through October 12 Swiss time.

The politics are unusually clean. Polypeptide Group’s board unanimously endorsed the deal, and IFBC – the Swiss-accredited independent valuation body that must sign off on fairness opinions in cross-border takeovers – confirmed the offer price is fair. The largest shareholder, Draupnir Holding, which owns 55.65 percent of Polypeptide Group, has already committed its entire stake to the tender offer. That alone clears the most difficult hurdle: getting enough shares off the table to reach the two-thirds threshold needed to close.

Samsung Biologics said it expects to finalize the acquisition by late November, assuming regulatory approvals fall into place. Once it crosses 90 percent ownership, it will delist Polypeptide Group from the Swiss exchange and trigger a squeeze-out of the remaining minority shareholders – a standard but forceful move that leaves no question about who runs the company going forward.

Why Peptides? Why Now?

The timing is not accidental. Peptide drugs are one of the fastest-growing segments in pharmaceuticals. Semaglutide, the GLP-1 agonist behind Novo Nordisk’s Wegovy and Ozempic, is a peptide. Tirzepatide from Eli Lilly, another peptide, is on a similar trajectory. Demand for these molecules is reshaping the global manufacturing landscape, and the CDMO players best positioned to serve that demand will capture disproportionate value over the next decade.

Polypeptide Group has spent decades building exactly that kind of capability. Based in Basel, the company specializes in solid-phase peptide synthesis and purification – the chemistry-heavy, precision manufacturing that makes peptide drugs possible at scale. That is not the same as the protein and antibody work Samsung Biologics has been mastering since its inception. Peptide synthesis is closer to traditional pharma chemistry than biologics. It requires different facilities, different regulatory relationships, and a different talent profile.

Samsung Biologics is betting that combining its manufacturing scale and operational expertise with Polypeptide Group’s peptide chemistry DNA creates something neither company could achieve alone.

The company explicitly stated that existing CDMO contracts will transfer to Samsung Biologics upon closing, stabilizing revenue from day one. It also said it will evaluate expanding production capacity for peptides as the market grows – a signal that Samsung sees room to grow rather than simply absorbing what exists.

The Lonza and Catalent Question

The global CDMO market remains dominated by a handful of Western players, led by Lonza and Catalent. Both have peptide capabilities, but neither has the Korean-scale manufacturing footprint that Samsung Biologics is building in Paju. Samsung has spent the past decade constructing what is arguably the largest single-site biomanufacturing campus in the world, with over 800,000 liters of downstream capacity already operational and more coming online.

What Samsung lacks – and what this acquisition closes – is a credible, integrated peptide offering. Lonza and Catalent already advertise end-to-end solutions that span small molecule, peptide, and biologic manufacturing. Samsung was missing a piece of that puzzle. Polypeptide Group fills it.

The strategic logic mirrors the semiconductor logic that built Samsung’s reputation: acquire the missing capability, integrate it under one roof, and compete on speed, scale, and cost. It is a very different M&A philosophy from the traditional pharma playbook, which tended toward inorganic growth in the specific therapeutic area of interest. Samsung is approaching CDMO the way it approached memory chips – by acquiring the best player in each segment and then out-building them on manufacturing excellence.

What This Means for Clients and Competitors

For drug developers, the story is straightforward: one more global CDMO option with genuine scale and a growing portfolio. That is good for the industry. It introduces real competitive pressure on pricing and lead times, which have been stretched thin by the GLP-1 boom.

For Lonza and Catalent, the threat is not existential but it is real. Samsung Biologics does not yet have a peptide franchise, but it does have capital, a track record of execution, and a willingness to move aggressively. The Polypeptide Group acquisition changes that equation immediately.

For smaller CDMOs, the warning sign is more urgent. Consolidation at this scale compresses the middle of the market. Companies that cannot offer an integrated portfolio across modalities face increasing difficulty winning mandates from large pharmaceutical sponsors who increasingly prefer single-vendor relationships.

The Closing Details That Matter

The key variable is whether the 66.7 percent threshold is crossed and whether antitrust reviews proceed smoothly. Samsung already controls a dominant position in biomanufacturing, so regulators in multiple jurisdictions will scrutinize how the combined entity competes. The Swiss and Korean authorities will likely clear this without difficulty. The more interesting review could come from the EU and potentially China, where Samsung is building additional capacity and where peptide manufacturing demand is accelerating.

If the deal closes, Samsung Biologics effectively becomes a full-stack CDMO – antibodies, ADCs, mRNA, and peptides under one corporate umbrella. That is a rare configuration, and it is one that only two or three companies globally can claim today.

The 11.6 percent premium suggests Samsung was willing to pay for certainty. The unanimous board endorsement and the majority shareholder’s commitment made a friendly, speedy close almost guaranteed. That is a luxury not every CDMO acquisition enjoys.

Samsung Biologics is no longer just a biomanufacturing contractor. It is assembling a global pharma services platform, and the Polypeptide Group deal is the clearest signal yet that it intends to compete with Lonza on its own terms – with more capital, faster execution, and a manufacturing culture that treats scale as a competitive weapon rather than a convenience.